Navigation Links
Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

RICHMOND, Calif., March 29, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3.20 pm ET on Tuesday, April 5, 2011 at the 10th Annual Needham Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
4. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... Maryland (PRWEB) , ... September ... ... proudly announces the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting ... accelerating clinical translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl ...
(Date:9/14/2017)... ... September 14, 2017 , ... AxioMed is pleased ... Australia. Dr. Steven Yang completed the procedure on a 35-year-old female patient suffering ... lumbar disc at level L5-S1. The patient failed conservative treatments prior to undergoing ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/13/2017)... (PRWEB) , ... September 13, 2017 , ... ... with the life sciences industry to improve patient outcomes and quality of life ... & impurities, has been named a US expert to the International Standards ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):